BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18709371)

  • 1. [Ovarian carcinoma. Do the subtypes reflect different diseases?].
    Köbel M
    Pathologe; 2008 Nov; 29 Suppl 2():160-2. PubMed ID: 18709371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer update: lessons from morphology, molecules, and mice.
    Cho KR
    Arch Pathol Lab Med; 2009 Nov; 133(11):1775-81. PubMed ID: 19886711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
    Morency E; Leitao MM; Soslow RA
    Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ovarian cancer--modern approach to its origin and histogenesis].
    Nowak-Markwitz E; Spaczyński M
    Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
    Moss EL; Evans T; Pearmain P; Askew S; Singh K; Chan KK; Ganesan R; Hirschowitz L
    Int J Gynecol Cancer; 2015 Sep; 25(7):1201-7. PubMed ID: 26035124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.
    Meinhold-Heerlein I; Fotopoulou C; Harter P; Kurzeder C; Mustea A; Wimberger P; Hauptmann S; Sehouli J
    Arch Gynecol Obstet; 2016 Apr; 293(4):695-700. PubMed ID: 26894303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. My approach to and thoughts on the typing of ovarian carcinomas.
    McCluggage WG
    J Clin Pathol; 2008 Feb; 61(2):152-63. PubMed ID: 17704261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
    Guo DH; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
    [No Abstract]   [Full Text] [Related]  

  • 12. Histological classification of ovarian cancer.
    Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
    Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
    Gurung A; Hung T; Morin J; Gilks CB
    Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
    Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathology of ovarian cancer.
    Sanseverino F; D'Andrilli G; Petraglia F; Giordano A
    Anal Quant Cytol Histol; 2005 Jun; 27(3):121-4. PubMed ID: 16121632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
    Devouassoux-Shisheboran M; Genestie C; Ray-Coquard I
    Bull Cancer; 2016 Mar; 103(3):252-8. PubMed ID: 26853278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early malignant changes in ovarian epithelium--the relationship between histology and molecular biological change].
    Ichikawa Y
    Hum Cell; 2000 Mar; 13(1):3-6. PubMed ID: 10937341
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas.
    Waldstrøm M; Grove A
    Arch Pathol Lab Med; 2005 Jan; 129(1):85-8. PubMed ID: 15628914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.